Tag: biosimilars

Learn how the 12-year biologic exclusivity rule under the BPCIA delays biosimilar entry, impacting drug prices and patient access in the US compared to global markets.

Generic drugs saved the U.S. healthcare system $3.4 trillion from 2015-2024. Learn how Hatch-Waxman, biosimilars, and market competition drive these massive savings and what challenges remain.

A deep dive into the Asian generic pharmaceutical landscape, comparing India's volume dominance with China's API control and the rise of emerging hubs.

Biosimilars aren't exact copies of biologics - tiny manufacturing differences can trigger immune responses. Learn why some patients develop antibodies, how administration and genetics affect risk, and what real-world data really shows.